C9 Antikörper (FITC)

Produktnummer ABIN1106799

Der FITC-konjugierte Maus Monoklonal anti-C9 Antikörper (Klon aE11) (ABIN1106799) detektiert spezifisch C9 in IHC (p), IF, EIA, Func und IHC (fro). Dieser Antikörper reagiert spezifisch mit Proben aus Human, Pferd und Schwein.

Kurzübersicht für C9 Antikörper (FITC) (ABIN1106799)

Target: C9 (Complement Component C9 (C9))

Reaktivität: Human, Pferd, Schwein

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser C9 Antikörper ist konjugiert mit FITC

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF), Enzyme Immunoassay (EIA), Functional Studies (Func), Immunohistochemistry (Frozen Sections) (IHC (fro))

Klon: AE11

Produktdetails anti-C9 Antikörper (FITC)

Kreuzreaktivität (Details): Species reactivity (tested):Human, horse, pig

Aufreinigung: Protein G

Isotyp: IgG2a

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.1 mg/mL

Buffer: PBS, 0.02 % sodium azide, 0.1 % bovine serum albumin

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2 - 8 °C.

Details zu C9

Target: C9 (Complement Component C9 (C9))

Andere Bezeichnung: Complement C9

Hintergrund: The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 Molecules associate with the C5b678 complex, which is also termed the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components. C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.Synonyms: Complement 9, Complement component C9

UniProt: P02748

Pathways: Komplementsystem